MorphoSys AG
XETRA:MOR
MorphoSys AG
Net Income (Common)
MorphoSys AG
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
MorphoSys AG
XETRA:MOR
|
Net Income (Common)
-€189.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
BioNTech SE
NASDAQ:BNTX
|
Net Income (Common)
€930.3m
|
CAGR 3-Years
296%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
CureVac NV
NASDAQ:CVAC
|
Net Income (Common)
-€260.2m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
Immatics NV
NASDAQ:IMTX
|
Net Income (Common)
-€97m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Net Income (Common)
€127m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-7%
|
CAGR 10-Years
15%
|
|
Formycon AG
XETRA:FYB
|
Net Income (Common)
€36m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is MorphoSys AG's Net Income (Common)?
Net Income (Common)
-189.7m
EUR
Based on the financial report for Dec 31, 2023, MorphoSys AG's Net Income (Common) amounts to -189.7m EUR.
What is MorphoSys AG's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-28%
Over the last year, the Net Income (Common) growth was -26%.